Shionogi's RSV antiviral shows promise in hVIVO trial
LONDON - Shionogi & Co., Ltd. (TYO:4507) has reported positive outcomes from its Phase 2a human challenge trial for an ...
Inhalon launches human challenge trial for RSV treatment
US-based Inhalon Biopharma is set to launch a trial of its at-home nebulised treatment for respiratory syncytial virus (RSV) ...
SBS4d
It's the biggest cause of infants being hospitalised. Now, protection is more available
Thousands of infants are hospitalised with respiratory syncytial virus (RSV) every year in Australia, with infections spiking between March and August. A study published in the Medical Journal of ...
clinicaltrialsarena5d
Inhalon launches human challenge trial for RSV treatment
Credit: Shutterstock / Berit Kessler. US-based Inhalon Biopharma is set to launch a trial of its at-home nebulised treatment for respiratory syncytial virus (RSV) as part of FluCamp. Inhalon’s ...
Daily Hive5d
What Canadians should know about RSV and how to prevent it this winter
This time of year, respiratory illnesses are everywhere — and one you might not know much about is respiratory syncytial virus, aka RSV. RSV isn’t a new virus by any means, but despite it being common ...
pharmaphorum5d
Shionogi takes Akili’s ADHD digital therapy to Japan
Digital health company Akili is on the brink of its first major expansion beyond the US, partnering with Shionogi to file a localised version of its attention deficit hyperactivity disorder (ADHD ...
pharmaphorum4d
COVID-19 and the digital pharma marketing revolution
Dan Atkins, vice president of digital innovation and insight at Shionogi Europe, told the conference in a keynote address that the company needed to get better insights into its customers as the ...
Yahoo Finance4d
Shionogi & Co., Ltd. (4507.T)
9735.T SECOM CO., LTD.